HUMAN HEALTH (01419) releases interim results, with a net profit attributable to shareholders of approximately HK$18.3 million, representing an 8.5% increase year-on-year.

date
18:07 26/02/2026
avatar
GMT Eight
Yingke Medical (01419) announced its interim results as of December 31, 2025 for the six months ending (mid-year of fiscal year 2026), with revenue of approximately HK$342 million, an increase of approximately HK$26.6 million or 8.4% compared to the mid-year of fiscal year 2025. The attributable profit to the owners of the Company was approximately HK$18.3 million, an increase of approximately HK$1.5 million or 8.5% compared to the mid-year of fiscal year 2025. Basic earnings per share were approximately 4.8 Hong Kong cents.
HUMAN HEALTH (01419) announced its interim performance for the six months ending on December 31, 2025 (mid-year of the 2026 fiscal year), with revenue of approximately HK$342 million, an increase of approximately HK$26.6 million or 8.4% compared to the mid-year of the 2025 fiscal year. The profit attributable to owners of the company is approximately HK$18.3 million, an increase of approximately HK$1.5 million or 8.5% compared to the mid-year of the 2025 fiscal year, with basic earnings per share of approximately 4.8 HK cents. The announcement stated that the revenue growth generated by the group's general medical services was mainly due to an increase in the number of patient visits and offset by a decrease in average spending per visit.